Literature DB >> 27292222

Nanomedicines for kidney diseases.

Ryan M Williams1, Edgar A Jaimes2, Daniel A Heller3.   

Abstract

Nanomedicines have been the subject of great interest for the treatment, diagnosis, and research of disease; however, few specifically address kidney disorders. Nanotechnology can confer significant benefits to medicine, such as the targeted delivery of drugs to specific tissues. Nanomedicines in the clinic have increased drug solubility, reduced off-target side effects, and provided novel diagnostic tools. There is an increasing cohort of nanomaterials that may have implications for kidney disease. Here, we review nanomaterial properties that are potentially applicable to kidney research and therapy, and we highlight clinical areas of need that may benefit from kidney nanomedicines.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diagnostics; drug development; imaging; nanoparticles; theranostics; therapeutics

Mesh:

Year:  2016        PMID: 27292222      PMCID: PMC5064150          DOI: 10.1016/j.kint.2016.03.041

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  67 in total

1.  Gold nanoparticle sensors for detecting chronic kidney disease and disease progression.

Authors:  Ophir Marom; Farid Nakhoul; Ulrike Tisch; Ala Shiban; Zaid Abassi; Hossam Haick
Journal:  Nanomedicine (Lond)       Date:  2012-03-08       Impact factor: 5.307

Review 2.  Nanomedicine(s) under the microscope.

Authors:  Ruth Duncan; Rogerio Gaspar
Journal:  Mol Pharm       Date:  2011-10-26       Impact factor: 4.939

Review 3.  Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells.

Authors:  M E M Dolman; S Harmsen; G Storm; W E Hennink; R J Kok
Journal:  Adv Drug Deliv Rev       Date:  2010-08-16       Impact factor: 15.470

Review 4.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

Authors:  Donald E Owens; Nicholas A Peppas
Journal:  Int J Pharm       Date:  2005-11-21       Impact factor: 5.875

5.  Single application of low-dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis.

Authors:  A J Suana; G Tuffin; B M Frey; L Knudsen; C Mühlfeld; S Rödder; H-P Marti
Journal:  J Pharmacol Exp Ther       Date:  2011-02-24       Impact factor: 4.030

6.  Coenzyme Q10 in essential hypertension.

Authors:  V Digiesi; F Cantini; A Oradei; G Bisi; G C Guarino; A Brocchi; F Bellandi; M Mancini; G P Littarru
Journal:  Mol Aspects Med       Date:  1994

Review 7.  Nanoparticle-based theranostic agents.

Authors:  Jin Xie; Seulki Lee; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2010-08-04       Impact factor: 15.470

8.  Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure.

Authors:  Hisataka Kobayashi; Sang-Kyung Jo; Satomi Kawamoto; Hideo Yasuda; Xuzhen Hu; Michael V Knopp; Martin W Brechbiel; Peter L Choyke; Robert A Star
Journal:  J Magn Reson Imaging       Date:  2004-09       Impact factor: 4.813

9.  Ferumoxytol for treating iron deficiency anemia in CKD.

Authors:  Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira
Journal:  J Am Soc Nephrol       Date:  2008-06-04       Impact factor: 10.121

10.  Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing.

Authors:  Shan Gao; San Hein; Frederik Dagnæs-Hansen; Kathrin Weyer; Chuanxu Yang; Rikke Nielsen; Erik I Christensen; Robert A Fenton; Jørgen Kjems
Journal:  Theranostics       Date:  2014-08-13       Impact factor: 11.556

View more
  14 in total

1.  Selective Nanoparticle Targeting of the Renal Tubules.

Authors:  Ryan M Williams; Janki Shah; Helen S Tian; Xi Chen; Frederic Geissmann; Edgar A Jaimes; Daniel A Heller
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

Review 2.  Novel Drug Delivery Technologies and Targets for Renal Disease.

Authors:  Alejandro R Chade; Gene L Bidwell
Journal:  Hypertension       Date:  2022-06-02       Impact factor: 9.897

3.  Study of Renal Accumulation of Targeted Polycations in Acute Kidney Injury.

Authors:  Weimin Tang; Sudipta Panja; Chinmay M Jogdeo; Siyuan Tang; Ao Yu; David Oupický
Journal:  Biomacromolecules       Date:  2022-04-08       Impact factor: 6.978

4.  Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury.

Authors:  Sang Jun Han; Ryan M Williams; Vivette D'Agati; Edgar A Jaimes; Daniel A Heller; H Thomas Lee
Journal:  Kidney Int       Date:  2020-02-22       Impact factor: 10.612

5.  Renal proximal tubular NEMO plays a critical role in ischemic acute kidney injury.

Authors:  Sang Jun Han; Ryan M Williams; Mihwa Kim; Daniel A Heller; Vivette D'Agati; Marc Schmidt-Supprian; H Thomas Lee
Journal:  JCI Insight       Date:  2020-09-17

6.  Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis.

Authors:  Chang Seong Kim; Ansuja Pulickal Mathew; Arathy Vasukutty; Saji Uthaman; Soo Yeon Joo; Eun Hui Bae; Seong Kwon Ma; In-Kyu Park; Soo Wan Kim
Journal:  J Nanobiotechnology       Date:  2021-04-17       Impact factor: 10.435

7.  Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules.

Authors:  Ernest L Vallorz; Karen Blohm-Mangone; Rick G Schnellmann; Heidi M Mansour
Journal:  AAPS J       Date:  2021-06-24       Impact factor: 3.603

Review 8.  Potential Applications of Nanotechnology in Urological Cancer.

Authors:  Ming-Hui He; Li Chen; Ting Zheng; Yu Tu; Qian He; Hua-Lin Fu; Ju-Chun Lin; Wei Zhang; Gang Shu; Lili He; Zhi-Xiang Yuan
Journal:  Front Pharmacol       Date:  2018-07-09       Impact factor: 5.810

9.  Accurate Monitoring of Renal Injury State through in Vivo Magnetic Resonance Imaging with Ferric Coordination Polymer Nanodots.

Authors:  Xiaodong Li; Hongda Chen; Fuyao Liu; Yixin Chen; Huimao Zhang; Zhenxin Wang
Journal:  ACS Omega       Date:  2018-05-04

Review 10.  Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery.

Authors:  Xiangsheng Liu; Jinhong Jiang; Huan Meng
Journal:  Theranostics       Date:  2019-10-17       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.